For patients who had IDH1-mutant ICC, ClarIDHy, a multicenter phase III study, validated the therapeutic efficacy of ivosidenib (IDH1 mutation inhibitor), reporting a mOS of 10.8 months and a mPFS of 2.7 months [86]. Here, IDH1 is linked to intrahepatic cholangiocarcinoma.